# Viatris Innovation GmbH clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Viatris Innovation GmbH as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Viatris Innovation GmbH: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/viatris-innovation-gmbh

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 29, 2026 | NCT07615868 | A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome | Viatris Innovation GmbH | Phase 1 | Completed | Chronic Coronary Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615868) |
| December 24, 2025 | NCT07301723 | A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301723) |
| October 1, 2025 | NCT07201129 | A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment | Viatris Innovation GmbH | Phase 3 | Recruiting | Nephritis, Lupus, Lupus Erythematosus, Systemic | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07201129) |
| August 20, 2025 | NCT07133191 | A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07133191) |
| June 26, 2024 | NCT06475742 | Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus | Viatris Innovation GmbH | Phase 3 | Enrolling by invitation | Lupus Erythematosus, Systemic | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06475742) |
| January 5, 2023 | NCT05672576 | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | Viatris Innovation GmbH | Phase 3 | Active not recruiting | Lupus Erythematosus, Systemic | 451 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05672576) |
| December 13, 2022 | NCT05648500 | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Viatris Innovation GmbH | Phase 3 | Active not recruiting | Lupus Erythematosus, Systemic | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05648500) |
| August 13, 2021 | NCT05004311 | The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics | Viatris Innovation GmbH | Phase 1 | Completed | Healthy, Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05004311) |
| July 12, 2021 | NCT04957719 | Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | Viatris Innovation GmbH | Phase 3 | Enrolling by invitation | Acute Myocardial Infarction | 25,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04957719) |
| March 29, 2021 | NCT04819464 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod | Viatris Innovation GmbH | Phase 1 | Completed | Healthy, Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04819464) |
| September 21, 2020 | NCT04557280 | A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04557280) |
| May 29, 2020 | NCT04406896 | The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects, Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04406896) |
| February 5, 2020 | NCT04255277 | To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of... | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04255277) |
| August 9, 2019 | NCT04052360 | Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04052360) |
| January 23, 2019 | NCT03814200 | A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subject | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03814200) |
| November 15, 2018 | NCT03742037 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | Viatris Innovation GmbH | Phase 2 | Completed | Systemic Lupus Erythematosus | 427 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03742037) |
| July 20, 2018 | NCT03593278 | A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03593278) |
| April 4, 2018 | NCT03487445 | A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack | Viatris Innovation GmbH | Phase 2 | Completed | Acute Myocardial Infarction | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03487445) |
| February 13, 2018 | NCT03430661 | A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects | Viatris Innovation GmbH | Phase 1 | Completed | Healthy | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03430661) |
| December 28, 2017 | NCT03384966 | A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease | Viatris Innovation GmbH | Phase 2 | Completed | Stable Coronary Artery Disease | 346 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03384966) |
| June 2, 2017 | NCT03173625 | A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the... | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03173625) |
| September 26, 2016 | NCT02914223 | A Study to Evaluate Cenerimod in Healthy Male Subjects | Viatris Innovation GmbH | Phase 1 | Completed | Healthy Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02914223) |
| June 24, 2015 | NCT02479204 | Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 | Viatris Innovation GmbH | Phase 1 | Terminated | Healthy Subjects | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02479204) |
| June 16, 2015 | NCT02472795 | Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic... | Viatris Innovation GmbH | Phase 1/2 | Completed | Systemic Lupus Erythematosus | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02472795) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 3 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Enrolling by invitation | 2 |
| Active not recruiting | 2 |
| Terminated | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lupus Erythematosus, Systemic | 6 |
| Connective Tissue Diseases | 4 |
| Immune System Diseases | 3 |
| Autoimmune Diseases | 3 |
| Skin and Connective Tissue Diseases | 1 |
| Lupus Nephritis | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Customs brokers in the United States](https://specstream.ai/data/businesses/customs-brokers/united-states)
- [Ski resorts in the United States](https://specstream.ai/data/businesses/ski-resorts/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [Welding supply stores in the United States](https://specstream.ai/data/businesses/welding-supply-stores/united-states)
